The Discovery of<i>N</i>-((2<i>H</i>-Tetrazol-5-yl)methyl)-4-((<i>R</i>)-1-((5<i>r</i>,8<i>R</i>)-8-(<i>tert</i>-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl)-4,4-dimethylpentyl)benzamide (SCH 900822): A Potent and Selective Glucagon Receptor Antagonist
Duane E. DeMong(Merck & Co., Inc., Rahway, NJ, USA (United States)), He Zhao(Institute of Process Engineering), Guowei Zhou(Nanjing University of Chinese Medicine), Mark C. Liang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Paul E. McNamara(Merck & Co., Inc., Rahway, NJ, USA (United States)), Diane E. Grotz, J.K.Y. Wong, Joyce Hwa, Jean E. Lachowicz, Christopher Sondey(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peishan Lin(Albany Molecular Research (United States)), Michael A. Miller(Pennsylvania State University), Yang Cao(Dalian Medical University), Andrew W. Stamford(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jolicia F. Gauuan(Albany Molecular Research (United States)), Ping Chen(Tea Research Institute), William J. Greenlee, Deyi Yang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kathleen Cox(Merck & Co., Inc., Rahway, NJ, USA (United States)), Brian J. Lavey(Merck & Co., Inc., Rahway, NJ, USA (United States)), Teresa Andreani(Scuola Superiore Sant'Anna), Prudence Bradley(Merck & Co., Inc., Rahway, NJ, USA (United States)), Joseph A. Kozlowski, Bhuneshwari Patel(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hongtao Zhang(Chinese Academy of Sciences), Wensheng Yu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ling Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xing Dai(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ying Zhai(First Affiliated Hospital of Wannan Medical College), Peng Dai(Albany Molecular Research (United States)), Michael Wong(Merck & Co., Inc., Rahway, NJ, USA (United States)), Aileen Soriano(Merck & Co., Inc., Rahway, NJ, USA (United States)), Richard A. Morrison(Merck & Co., Inc., Rahway, NJ, USA (United States)), Tao Meng(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kung‐I Feng(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jitendra D. Belani(Albany Molecular Research (United States)), Sue‐Ing Lin(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 20
Related Papers
National Survey of Drug-Resistant Tuberculosis in China
|New England Journal of Medicine|2012|649
ErbB receptors: from oncogenes to targeted cancer therapies
|Journal of Clinical Investigation|2007|578
Advances in clinical immunotherapy for gastric cancer
|Biochimica et Biophysica Acta (BBA) - Reviews on Cancer|2021|435
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients
|Science Translational Medicine|2016|416
Degradable Carbon Dots with Broad-Spectrum Antibacterial Activity
|ACS Applied Materials & Interfaces|2018|407